Methoxetamine: A Foe or Friend?

Simple item page
dc.contributor.authorBotanas, Chrislean Jun
dc.contributor.authorde la Peña, June Bryan
dc.contributor.authorKim, Hee Jin
dc.contributor.authorLee, Yong Sup
dc.contributor.authorCheong, Jae Hoon
dc.contributor.utdAuthorde la Peña, June Bryan
dc.date.accessioned2020-04-14T22:40:55Z
dc.date.available2020-04-14T22:40:55Z
dc.date.issued2018-10-24
dc.descriptionDue to copyright restrictions and/or publisher's policy full text access from Treasures at UT Dallas is limited to current UTD affiliates (use the provided Link to Article).
dc.descriptionSupplementary material is available on publisher's website. Use the DOI link below.
dc.description.abstractMethoxetamine (MXE) is an N-methyl-D-aspartate (NMDA) receptor antagonist that is chemically and pharmacologically similar to other dissociative substances, such as ketamine and phencyclidine. There are reports on the misuse of MXE, which sometimes resulted in adverse consequences and death. Studies have also shown that MXE has abuse liability and stimulates dopamine neurotransmission in the mesolimbic reward pathway in the brain. These findings have contributed to the negative impression on MXE. However, recent preclinical studies have identified the antidepressant properties of MXE, which are attributed to its ability to affect the glutamatergic and serotonergic systems. MXE is also reported to have analgesic effects. These findings show some of the "redeeming qualities" of MXE and indicate its possible therapeutic uses. In this paper, we have reviewed the findings that provide insights into the adverse and potential therapeutic effects of MXE. We compiled studies on the toxicity, psychotomimetic effects, and abuse liability of MXE, as well as its promising antidepressant and analgesic properties. We also have discussed the mechanism of action that might mediate the somewhat paradoxical effects observed. Importantly, this review provides valuable information on MXE for future research and will enable a better understanding of its psychopharmacological properties and the mechanisms responsible for its unique effects.
dc.description.departmentSchool of Natural Sciences and Mathematics
dc.description.sponsorshipBio and Medical Technology Development Program of the National Research Foundation and the Korean government (MSIT) (NRF-2017M3A9G2077568); the National Research Foundation of Korea (2017R1D1A1A02018695); Ministry of Food and Drug Safety of Korea (14182MFDS979)
dc.identifier.bibliographicCitationBotanas, Chrislean Jun, June Bryan de la Peña, Hee Jin Kim, Yong Sup Lee, et al. 2019. "Methoxetamine: A foe or friend?." Neurochemistry International 122: 1-7, doi: 10.1016/j.neuint.2018.10.020
dc.identifier.issn0197-0186
dc.identifier.urihttp://dx.doi.org/10.1016/j.neuint.2018.10.020
dc.identifier.urihttps://hdl.handle.net/10735.1/7972
dc.identifier.volume122
dc.language.isoen
dc.publisherPergamon-Elsevier Science Ltd
dc.rights©2018 Elsevier Ltd.
dc.source.journalNeurochemistry International
dc.subjectKetamine
dc.subjectPsychotropic drugs
dc.subjectDesigner drugs
dc.subjectDepressed persons
dc.subject.mesh2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone
dc.subject.meshAntidepressive Agents
dc.subject.meshPrepulse Inhibition
dc.subject.meshReceptors, AMPA
dc.subject.meshBrain-Derived Neurotrophic Factor
dc.subject.meshDepression
dc.titleMethoxetamine: A Foe or Friend?
dc.type.genrearticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
NSM-2079-261184.71-LINK.pdf
Size:
164.45 KB
Format:
Adobe Portable Document Format
Description:
Link to Article
Download

Collections

NSM Staff-Student Research